Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia

Author(s):  
Fatma Sa'eed El-Tokhy ◽  
Mona M.A. Abdel-Mottaleb ◽  
Elsayed A. El-Ghany ◽  
Ahmed S. Geneidi
1991 ◽  
Vol 3 (1) ◽  
pp. 25 ◽  
Author(s):  
JD Curlewis ◽  
AM Sibbald ◽  
JA Milne ◽  
AS McNeilly

The aim of this study was to determine whether suppression of the seasonal increase in prolactin concentrations by chronic treatment with the dopamine agonist bromocriptine would affect onset of anoestrus, voluntary food intake, body weight, and wool growth in a seasonal breed of sheep. Groups of eight Scottish Blackface ewes were injected i.m. each week with either the vehicle (Group A) or 2.0 mg (Group B), 6.0 mg (Group C), or 18.0 mg (Group D) of bromocriptine in a long-acting formulation, commencing on 18 January and terminating on 25 July (midwinter to midsummer in the northern hemisphere). Immediately before the bromocriptine injection, blood samples were taken for progesterone and prolactin determination. Voluntary food intakes were measured daily, and body weights were recorded every fortnight. Estimates of wool growth were made by weighing wool clipped from a measured area of skin once a month. Treatment had no effect on onset of anoestrus, voluntary food intake, body weight, or wool growth. Plasma prolactin concentrations increased significantly in all groups during the treatment period. From January to April, all doses of bromocriptine significantly reduced prolactin concentrations but later in the study (May and June) prolactin was significantly suppressed in Group D only, although even in this group prolactin concentrations increased between March and June. Pituitary prolactin content, measured at the end of the study in July, was also suppressed by bromocriptine. The gradual increase in prolactin concentrations in ewes receiving chronic bromocriptine was further investigated by treating a fifth group of ewes (Group E) with 18.0 mg of long-acting bromocriptine each week, commencing on 20 June.(ABSTRACT TRUNCATED AT 250 WORDS)


Hypertension ◽  
2007 ◽  
Vol 49 (2) ◽  
pp. 285-290 ◽  
Author(s):  
Isabella Sudano ◽  
Agostino Virdis ◽  
Stefano Taddei ◽  
Lukas Spieker ◽  
Roberto Corti ◽  
...  

2003 ◽  
Vol 88 (11) ◽  
pp. 5258-5265 ◽  
Author(s):  
Roberto Attanasio ◽  
Roberto Baldelli ◽  
Rosario Pivonello ◽  
Silvia Grottoli ◽  
Liliana Bocca ◽  
...  

1990 ◽  
Vol 13 (1) ◽  
pp. 69-72 ◽  
Author(s):  
Elio Roti ◽  
R. Minelli ◽  
E. Gardini ◽  
M. Salvi ◽  
L. Bianconi ◽  
...  

1991 ◽  
Vol 125 (5) ◽  
pp. 494-501 ◽  
Author(s):  
Caterina Maraschini ◽  
Mirella Moro ◽  
Antonio Masala ◽  
Paola Toja ◽  
Sergio Alagna ◽  
...  

Abstract. Forty-one patients with prolactinoma (25 micro-, 16 macroprolactinomas) were treated with a long-acting injectable preparation of bromocriptine (Parlodel LAR®, Sandoz), 25-100 mg (mostly 50 mg) im every 4-8 weeks for as long as 43 months (median 19 months). The first injection caused a prompt fall of plasma PRL which reached its nadir value after 3 days. Thereafter, hormone levels remained well below initial values for 4 weeks or longer, though with the tendency, more pronounced in microprolactinoma patients, to rise again toward baseline. The prevalence of PRL normalization was greater in the macro- than in the microprolactinoma group. By repeated injections plasma PRL could be kept close to or within the normal limits in most of the patients. However, the extent of PRL inhibition was significantly greater in macro- than in microprolactinoma patients (p<0.01). Clinical improvement occurred in the majority of the patients, shrinkage of the tumour in 50% of them. Adverse reactions were generally mild or of moderate severity and subsided spontaneously in 24 h. They were less frequent (NS) and less severe (p<0.05) in macro- than in microprolactinoma patients. In conclusion: a. injectable bromocriptine (Parlodel LAR) is a highly effective preparation particularly suitable for the long-term treatment of tumourous hyperprolactinemia; b. patients with macroprolactinoma exhibit, compared with microprolactinoma patients, better responsiveness and better tolerability to injectable bromocriptine.


Sign in / Sign up

Export Citation Format

Share Document